Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life

By L. Locati, D. Galbiati, G. Calareso, S. Alfieri, S. Singer, S. Cavalieri, C. Bergamini, P. Bossi, E. Orlandi, C. Resteghini and 7 more. 2020

Subfields: Oncology, Otorhinolaryngology

Citations in the corpus

• Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review) (2025, unknown): “Locati et al (60) evaluated lenvatinib in patients with recurrent or metastatic ACC and found only three partial responses among 26 participants, with a median overall survival time of 27 months, a median progression‑free survival time of 9.1 months and a median duration of response of 3.1 months.”